Search results
Results from the WOW.Com Content Network
Topical hemostatic agents should not be used for routine prophylaxis of postoperative bleeding because these agents may increase the risk of infection, adhesion formation, and other complications. Topical hemostatic agents have distinct mechanisms of action, different potential adverse effect profiles, and varying costs.
Perioperative hemostatic agents include desmopressin acetate and antifibrinolytic medications (eg, aminocaproic acid, tranexamic acid). Currently, no standardized protocol exists for operative placement of the LNG-IUD in the patient with a bleeding disorder.
Topical Hemostatic Agents at Time of Obstetric and Gynecologic Surgery ...
Kadir RA, Lukes AS, Kouides PA, Fernandez H, Goudemand J. Management of excessive menstrual bleeding in women with hemostatic disorders. Fertil Steril 2005;84:1352–9. [ PubMed ] [Full Text]
Nonhormonal treatment options include antifibrinolytic agents, such as tranexamic acid and ε-aminocaproic acid 27 28, and treatments that increase endogenous plasma concentration of vWF, replace vWF, or promote hemostasis without affecting vWF. Antifibrinolytics inhibit the conversion of plasminogen to plasmin, which inhibits fibrinolysis and ...
Neither ACOG nor its officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.
No currently used anesthetic agents have been shown to have any teratogenic effects in humans when using standard concentrations at any gestational age. There is no evidence that in utero human exposure to anesthetic or sedative drugs has any effect on the developing fetal brain; and there are no animal data to support an effect with limited ...
Annotations. The CREOG Education Committee annotated the 13th edition of the CREOG Educational Objectives with educational resources listed in the first column in red, with Milestones listed in the second column in blue and with ACGME requirements listed where appropriate from the Common and OBGYN requirements in the third column in green.
ABSTRACT: Deep vein thrombosis (DVT) and pulmonary embolism (PE) are collectively referred to as “venous thromboembolic events” (VTE).
ABSTRACT: The purpose of this document is: 1) to help obstetrician–gynecologists better understand the U.S. Food and Drug Administration’s regulatory process for the marketing of medical devices; 2) to educate obstetrician–gynecologists on the importance of understanding available evidence on the safety, efficacy, and indications for devices in clinical practice; 3) to encourage ...